UNSPSC 51172131: Fenpiprane or fenpiprane hydrochloride

This classification denotes an antispasmotic agent with the molecular formulas C20H25N and C20H25N.ClH, and preparation that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers S2FVB1RL5X and C20H25N.ClH. European Medicines Agency schedules Fenpiprane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07589MIG.

UNSPSC 51172131 Fenpiprane or fenpiprane hydrochloride (Commodity) represents pharmaceutical products state and local governments buy primarily through cooperative purchasing vehicles and county-level specimen testing programs. Recent solicitations show the code encompasses generic pharmaceuticals and over-the-counter products distributed via state purchasing alliances, as well as prescription testing reagents and confirmatory materials used in drug screening operations. The issuing bodies include state health and human services agencies, state procurement offices administering multistate cooperative agreements, county criminal justice departments, and subordinate local health facilities. Texas Health and Human Services Commission and the Minnesota Department of Administration (administering the Multistate Cooperative Purchasing Alliance) are the primary repeat state-level buyers evident in recent activity, while Collin County, Texas represents county-level demand.

Recent activity clusters in Texas and Minnesota. The Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026 (due July 23, 2026) for offender specimen collection and drug testing services, including immunoassay screening with confirmatory LC/MS/MS or GC/MS testing across two sites in Plano and McKinney, with an estimated contract value of $600,000 and a two-year initial term commencing September 1, 2026. The Minnesota Department of Administration issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) through the Multistate Cooperative Purchasing Alliance for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon, with contract effectiveness set for July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription delivery models for a future Therapeutic Pharmacy Initiative program, signaling exploratory procurement activity ahead of formal solicitation.